Search alternatives:
ng decrease » nn decrease (Expand Search), _ decrease (Expand Search), gy decreased (Expand Search)
we decrease » _ decrease (Expand Search), nn decrease (Expand Search), mean decrease (Expand Search)
mm decrease » _ decrease (Expand Search), nn decrease (Expand Search), mean decrease (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
50 mm » 10 mm (Expand Search), 50 mg (Expand Search), 20 mm (Expand Search)
ng decrease » nn decrease (Expand Search), _ decrease (Expand Search), gy decreased (Expand Search)
we decrease » _ decrease (Expand Search), nn decrease (Expand Search), mean decrease (Expand Search)
mm decrease » _ decrease (Expand Search), nn decrease (Expand Search), mean decrease (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
50 mm » 10 mm (Expand Search), 50 mg (Expand Search), 20 mm (Expand Search)
-
7301
-
7302
-
7303
-
7304
-
7305
-
7306
-
7307
-
7308
-
7309
-
7310
Different scenarios of hidden hearing loss have additive effects on SGN activity.
Published 2021“…<p>(A) Sound-evoked CAPs of SGN fiber populations with different myelinopathy and synaptopathy scenarios at 70dB SPL, averaged over 50 simulations (dashed lines correspond to the peaks of each CAP, labeled with the same colors as the CAPs). …”
-
7311
-
7312
Keeping constant channel number as length of unmyelinated segment, <i>L</i><sub><i>u</i></sub>, is increased leads to similar effects on cumulative CAP as keeping constant channel...
Published 2021“…<p>(A)Sound-evoked CAPs of SGN fiber populations with varied <i>L</i><sub><i>u</i></sub> at 70dB SPL, averaged over 50 simulations (dashed lines correspond to the peaks of each CAP, labeled with the same colors as the CAPs). …”
-
7313
Maintaining channel density at the heminode as its length, <i>L</i><sub><i>h</i></sub>, is varied reduces effects on cumulative CAP compared to keeping constant channel number.
Published 2021“…<p>(A) Sound-evoked CAPs of SGN fiber populations with varied <i>L</i><sub><i>h</i></sub> at 70dB SPL, averaged over 50 simulations (dashed lines correspond to the peaks of each CAP, labeled with the same colors as the CAPs). …”
-
7314
-
7315
-
7316
Recycling of Single-Use Multilayer Plastics for Biomanufacturing with Solvent-Targeted Recovery and Precipitation
Published 2025“…Life cycle analysis shows STRAP consumes 50% less fossil fuel and produces 50% fewer greenhouse gas emissions than virgin PE production and achieves even greater reductions80% decrease in both fossil fuel use and emissionscompared to virgin EVOH production. …”
-
7317
Recycling of Single-Use Multilayer Plastics for Biomanufacturing with Solvent-Targeted Recovery and Precipitation
Published 2025“…Life cycle analysis shows STRAP consumes 50% less fossil fuel and produces 50% fewer greenhouse gas emissions than virgin PE production and achieves even greater reductions80% decrease in both fossil fuel use and emissionscompared to virgin EVOH production. …”
-
7318
Recycling of Single-Use Multilayer Plastics for Biomanufacturing with Solvent-Targeted Recovery and Precipitation
Published 2025“…Life cycle analysis shows STRAP consumes 50% less fossil fuel and produces 50% fewer greenhouse gas emissions than virgin PE production and achieves even greater reductions80% decrease in both fossil fuel use and emissionscompared to virgin EVOH production. …”
-
7319
Recycling of Single-Use Multilayer Plastics for Biomanufacturing with Solvent-Targeted Recovery and Precipitation
Published 2025“…Life cycle analysis shows STRAP consumes 50% less fossil fuel and produces 50% fewer greenhouse gas emissions than virgin PE production and achieves even greater reductions80% decrease in both fossil fuel use and emissionscompared to virgin EVOH production. …”
-
7320
Supplementary Material for: Off-label Use of Mycophenolate Mofetil in Immunoglobulin A Nephropathy: A Systematic Review and Meta-analysis
Published 2024“…Introduction: Mycophenolate mofetil (MMF) is widely used off-label in patients with immunoglobulin A nephropathy (IgAN), although the literature does not consistently agree on its efficacy and safety. …”